MDNAF Medicenna Therapeutics Corp

$MDNAF For a cash constrained coy, leverage is everything. MDNA209 preclinical readout is not about 209 entreing the clinic soon rather it is about strategic positioning- showing platform depth. It’s a strategic bait to create competitive tension &The message is clear- we’re not a single asset coy- We’re a superkine PLATFORM coy with repeatable & scalable biology capabe of generating multiple first-in-class molecule. Visibility is currency- synchronizing the release around this Q4 is even more symbolic- De risk the lead asset,Show pipeline depth, Increase partnership leverage by demonstrating multi asset optionality. we're opened for business, Partner(s) welcome

$MDNAF SITC 2026: this is the first time MDNA & its authors claimed efficacy. Across ASCO, ESMO, AACR, and SITC 2024–2025, MDNA used softer, neutral phrasing — never once an efficacy claim. The tone changed with SITC 2026, where MDNA11 used a headline level efficacy phrase, not one buried in the text. That’s a confidence signal. You don’t get to say “demonstrates clinical activity” unless reviewers see real, reproducible anti-tumor effect. authors pick the abstract title-not more than 200 characters, SITC reviews it for compliance — character limit, accuracy, and no exaggerated claims. SITC only allows efficacy type wording when reviewers agree the data truly support it. Out of all abstracts released so far, only MDNA11 claims in- human efficacy (“clinical activity”) in the title- This is extremely rare. In 2025 none of the abstracts made such a claim. SITC is conservative with clinical claims. Everyone who’s actually seen the data seems to agree on one thing — MDNA11 is crushing it.

$MDNAF Burkhard Becher- a world-leading Professor of Immunology & 2021 winner of The Johann Anton Merck Award. This Merck award is awarded to scientists whose work directly influence Merck’s future pipeline. The award is used to recognize breakthroughs Merck wants to stay close to. It is one of Merck’s earliest “tells” that they consider a platform scientifically important. Merck honoring Becher is a direct signal that cytokine based immune activation is a strategic pillar for them. What’s more, Becher is a member of Medicenna scientific advisory board! Becher Leads the Directorate of Experimental Immunology, University of Zürich (UZH). Medicenna’s new clinical site in Zurich (USZ) is the teaching hospital arm of this university. placing MDNA11 directly inside Becher’s scientific ecosystem. Becher a Merck award recipient is the leading authority for mechanistic validation.

$MDNAF Abstract Title posted…”Top 150” look cool!!! Abstract #517 Presents Friday, Nov. 6 Top 150 🎗 MDNA11 Demonstrates Clinical Activity as Monotherapy and in Combination with Pembrolizumab in Biomarker-Enriched Gastrointestinal Malignancies, Including ICI-Refractory Disease Presenting Author Andre Mansinho – START Lisbon, ULSSM – Hospital de Santa Maria,Gulbenkian Institute for Molecular Medicine,Faculty of Medicine, University of Lisbon Authors Andre Mansinho, Victoria Atkinson, Philippe Bedard, Pablo Gajate, Jacqueline Brown, Luis Cabezón-Gutiérrez, Austin Duffy, Victor Moreno, Kim Margolin, Przemyslaw Twardowski, Irene Moreno, Hong Shue, Ira Winer, Michael Chisamore, Marc Oliva, Amy Prawira, Fahar Merchant, Rosemina Merchant, William Gwynne, Minh To, Nageatte Ibrahim, Arash Yavari, Melissa Coello, Hussein Tawbi, Sara Coelho, Igor Medic, Tatiana Hernandez-Guerrero, Paolo Ascierto

$MDNAF The addition of the melanoma site in Zürich, which appears to be a highly respected melanoma centre, this late in the game ,is extremely encouraging. Medicenna is not gonna spend money on another site if the confidence in the data is not there… and it open label ..so they know… and Zurich surely has too!And it is just melanoma.

$MDNAF What is the Net Present Value of MDNA11 for treating melanoma when the drug hits the market in ‘28? NPV $960,682,775 Disc Finance Rate 30% Investment Cost ($25.0M) Profit Streams Yr ‘27 - 0 Yr ‘28 - $540.0M Yr ‘29 - $712.8M Yr ‘30 - $914.7M Yr ‘31 - $1,149.9M Assumption 1. The global Melanoma market will be $7.0B in ‘26 and has a CAGR of 10.0% and of that market 51.0% will have biomarkers TMB + HSI high Assumption 2. Big Pharma’s Cost-of-Capital for high risk assets is 30% and this will be our Discount Rate Assumption 3. Medicienna will probably incur costs of $25M on a global pivotal trial Assumption 4 I have MDNA11 being commercialized in ‘28 capturing 12.5% of the entire Global TMB + HSI in Year1’27, and increasing 2.5% annually to ‘31

$MDNAF Oct. 22, 2026 Medicenna Therapeutics Corp. (“Medicenna” or the “Company”)OTCQB: MDNAF), a clinical-stage immunotherapy co. developing Superkines for cancer and autoimmune diseases, announced that it will present new preclinical data on MDNA209, its pote first-in-class cytokine-based CD122 superantagonist. The landscape of CD122 therapy (targeting the beta subunit of the IL-2 and IL-15 receptors) has demonstrated growing clinical validation and increasing strategic interest for the treatment of autoimmune and inflammatory conditions such as celiac disease, eosinophilic esophagitis, graft-versus-host-disease, and vitiligo. MDNA209 is an engineered protein designed to block CD122 and inhibit signaling by IL-2 and IL-15, two immune signaling molecules that can sustain the hyperactivity of immune cells responsible for inflammation and tissue damage. The upcoming presentation will further characterize MDNA209’s potency and its differentiated approach to targeting these pathways.

$MDNAF Resolution passed… If they do a split before the next data dump it’s over boys and girls.

$MDNAF It's clear that every AI investor also holds MDNA in their portfolio......selling MDNA to raise cash to cover margin calls on their AI holdings........right? Right???